LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients
Abstract
Objective— Triglyceride-rich lipoproteins that contain apolipoprotein CIII (apoCIII) are prominent in diabetic dyslipidemia. We hypothesized that these lipoproteins increase coronary disease risk in diabetic patients beyond that caused by standard lipid risk factors. Methods and Results— Diabetic patients with previous myocardial infarction were followed for 5 years, and 121 who had a recurrent coronary event were matched to 121 who did not. VLDL and LDL that contained or did not contain apoCIII (CIII+ or CIII−) were prepared by immunoaffinity chromatography and ultracentrifugation. IDL was included in the LDL fraction. LDL CIII+, rich in cholesterol and triglyceride, was the strongest predictor of coronary events (relative risk [RR] 6.6, P <0.0001, for 4th versus 1st quartile). LDL CIII+ comprised 10% of total LDL. The main type of LDL, LDL CIII−, was less strongly predictive (RR 2.2, P =0.07). The increased risk associated with LDL CIII+ was unaffected by adjustment for plasma lipids, apoB, non-HDL cholesterol, or the other VLDL and LDL types. For VLDL CIII+, RR 0.5, P =0.07; for VLDL CIII−, RR 2.3, P =0.046. The presence of apolipoprotein E with CIII on VLDL and LDL did not affect risk. Conclusions— LDL with apoCIII strongly predicts coronary events in diabetic patients independently of other lipids and may be an atherogenic remnant of triglyceride-rich VLDL metabolism.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ApoCIII is a predictor of CV disease.
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
Reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles.
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · see citing works
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · see citing works
Diabetes and cardiovascular disease. The Framingham study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.241.19.2035 · Cited by 3,958 · see citing works
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936 · see citing works
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014 · see citing works
Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.23.2513 · Cited by 986 · see citing works
Self-citationFuller, J., Shipley, M. J., Rose, G., Jarrett, R. J., & KEEN, H. (1983) · BMJ · doi:10.1136/bmj.287.6396.867 · Cited by 632 · see citing works
Fontbonne, A., Eschw�ge, E., Cambien, F., Richard, J. L., Ducimeti�re, P., Thibult, N., Warnet, J., Claude, J., & Rosselin, G. (1989) · Diabetologia · doi:10.1007/bf00265546 · Cited by 616 · see citing works
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490 · see citing works
Self-citationGinsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424 · see citing works
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.
Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M.-R. (1997) · Diabetologia · doi:10.1007/s001250050700 · Cited by 319 · see citing works
Sehayek, E., & Eisenberg, S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55263-7 · Cited by 283 · see citing works
Lipoprotein lipase in diabetes
Taskinen, M. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030208 · Cited by 273 · see citing works
Krauss, R., Williams, P. T., Brensike, J. F., Detre, K. M., Lindgren, F. T., Kelsey, S. F., VRANIZAN, K. M., & Levy, R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92734-6 · Cited by 253 · see citing works
Atherogenicity of Triglyceride-Rich Lipoproteins
Krauss, R. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00032-0 · Cited by 227 · see citing works
The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding.
Weisgraber, K. H., Innerarity, T. L., Harder, K. J., Mahley, R. W., Milne, R. W., Marcel, Y. L., & Sparrow, J. T. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44181-0 · Cited by 220 · see citing works
Ebara, T., Ramakrishnan, R., Steiner, G. A., & Shachter, N. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119456 · Cited by 191 · see citing works
Alaupovic, P., Mack, W. J., Knight‐Gibson, C., & Hodis, H. N. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.4.715 · Cited by 184 · see citing works
Intermediate-Density Lipoproteins and Progression of Carotid Arterial Wall Intima-Media Thickness
Hodis, H. N., Mack, W. J., Dunn, M. E., Liu, C., Ci-hua, L., Selzer, R. H., & Krauss, R. M. (1997) · Circulation · doi:10.1161/01.cir.95.8.2022 · Cited by 155 · see citing works
Low density lipoprotein size, pravastatin treatment, and coronary events.
Campos, H. (2001) · JAMA · doi:10.1001/jama.286.12.1468 · Cited by 132 · see citing works
Self-citationGustafson, A., Alaupovic, P., & Furman, R. H. (1966) · Biochemistry · doi:10.1021/bi00866a033 · Cited by 126 · see citing works
Alaupovic, P. (1996) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(96)63004-3 · Cited by 110 · see citing works
Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM
Taskinen, M., Packard, C. J., & Shepherd, J. (1990) · Diabetes · doi:10.2337/diab.39.9.1017 · Cited by 103 · see citing works
Seeman, T. E., de Leon, C. F. M., Berkman, L. F., & Ostfeld, A. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116822 · Cited by 100 · see citing works
Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes
Gervaise, N., Garrigue, M. A., Lasfargues, G., & Lecomte, P. (2000) · Diabetologia · doi:10.1007/s001250051366 · Cited by 82 · see citing works
Role of triglyceride-rich lipoproteins in progression of atherosclerosis.
Havel, R. J. (1990) · Circulation · doi:10.1161/01.cir.81.2.694 · Cited by 80 · see citing works
Pietzsch, J., Subat, S., Nitzsche, S., et al. (1995) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(94)00171-t · Cited by 76 · see citing works
Campos, H., Perlov, D., Khoo, C., & Sacks, F. M. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31574-1 · Cited by 73 · see citing works
Self-citationChivot, L., Mainard, F., Bigot‐Corbel, E., Bard, J., Auget, J.-L., Madec, Y., & Fruchart, J. (1990) · Atherosclerosis · doi:10.1016/0021-9150(90)90042-h · Cited by 60 · see citing works
Lee, S.-J., Moye, L. A., Campos, H., Williams, G. H., & Sacks, F. M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00007-8 · Cited by 50 · see citing works
Self-citationDifferential Metabolism of Human VLDL According to Content of ApoE and ApoC-III
Tomiyasu, K., Walsh, B. W., Ikewaki, K., Judge, H., & Sacks, F. M. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0901.094489 · Cited by 46 · see citing works
Self-citationHyperinsulinemia and Triglyceride-Rich Lipoproteins
Steiner, G. A., & Lewis, G. F. (1996) · Diabetes · doi:10.2337/diab.45.3.s24 · Cited by 45 · see citing works
Khoo, C., Campos, H., Judge, H., & Sacks, F. M. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33358-7 · Cited by 37 · see citing works
Self-citationLeonhardt, W., Pietzsch, J., & Nitzsche, S. (1994) · Clinica Chimica Acta · doi:10.1016/0009-8981(94)90117-1 · Cited by 34 · see citing works
Identification of ApoB-Containing Lipoprotein Families in NIDDM
Alaupovic, P., Bard, J., Tavella, M. J., & Shafer, D. (1992) · Diabetes · doi:10.2337/diab.41.2.s18 · Cited by 32 · see citing works
Lindgren, F. T., Silvers, A., Jutagir, R., et al. (1977) · Lipids · doi:10.1007/bf02533347 · Cited by 27 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Alaupovic P. Significance of structure, function, and classification of plasma lipoprotein families. Methods Enzymol. 1996;263:32-60.
Cited by
Sorted by citations
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463 · see citing works
Self-citationTargeting inflammation in metabolic syndrome
Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.017 · Cited by 287 · see citing works
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282 · see citing works
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260 · see citing works
Self-citationHow Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?
Welty, F. K. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0400-4 · Cited by 221 · see citing works
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196 · see citing works
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182 · see citing works
Postprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182 · see citing works
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171 · see citing works
Sacks, F. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000146 · Cited by 168 · see citing works
Self-citationOscarsson, J., & Hurt-Camejo, E. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0541-3 · Cited by 158 · see citing works
Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects
Taskinen, M.-R., Adiels, M., Westerbacka, J., Söderlund, S., Kahri, J., Lundbom, N., Lundbom, J., Hakkarainen, A., Olofsson, S.-O., Orho-Melander, M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.224808 · Cited by 153 · see citing works
Mendivil, C. O., Zheng, C., Furtado, J., Lel, J., & Sacks, F. M. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.197830 · Cited by 145 · see citing works
Self-citationWyler von Ballmoos, M. C., Haring, B., & Sacks, F. M. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.002 · Cited by 134 · see citing works
Self-citationApolipoprotein CIII links dyslipidemia with atherosclerosis
Kawakami, A., & Yoshida, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e607 · Cited by 98 · see citing works
Chunyu, Z., Christina, K., Katsunori, I., & Sacks, F. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600011-jlr200 · Cited by 95 · see citing works
Self-citationAn ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan, D. C., Chen, M. M., Ooi, E. M. M., & Watts, G. F. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01678.x · Cited by 85 · see citing works
Stahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75 · see citing works
Apolipoprotein C-III: Going Back to the Future for a Lipid Drug Target
Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70 · see citing works
Campos, H., Khoo, C., & Sacks, F. M. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.12.045 · Cited by 58 · see citing works
Self-citationRole of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55 · see citing works
Apolipoprotein status in type 2 diabetes mellitus and its complications
Zhang, P., Gao, J., Pu, C., & Zhang, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7831 · Cited by 55 · see citing works
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0697-3 · Cited by 54 · see citing works
Olivieri, O., Martinelli, N., Sandri, M., Bassi, A., Guarini, P., Trabetti, E., Pizzolo, F., Girelli, D., Friso, S., Pignatti, P. F., et al. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.040477 · Cited by 50 · see citing works
Skulas-Ray, A. C., Alaupovic, P., Kris-Etherton, P. M., & West, S. G. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.12.001 · Cited by 30 · see citing works
Nakou, E. S., Filippatos, T. D., Agouridis, A. P., Kostara, C., Bairaktari, E. T., & Elisaf, M. S. (2010) · Lipids · doi:10.1007/s11745-010-3409-0 · Cited by 23 · see citing works
Furtado, J. D., Campos, H., Sumner, A. E., Appel, L. J., Carey, V. J., & Sacks, F. M. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28532 · Cited by 18 · see citing works
Self-citation
- Authors
- Lee, S.-J., Campos, H., Moye, L. A., & Sacks, F. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Department of Nutrition, Harvard School of Public Health (S.J.L., H.C., F.M.S.) and the Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital (F.M.S.), Boston, Mass, and University of Texas School of Public Health (L.A.M.), Houston, Tex. Dr Lee is presently at the Stanford School of Medicine, Calif.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2003-05
- Volume
- 23
- Issue
- 5
- Pages
- 853-858
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2148326332
- Cited by
- 170
- References
- 37
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 6 · 2020: 4 · 2019: 8 · 2018: 7 · 2017: 10 · 2016: 7 · 2015: 7 · 2014: 10 · 2013: 9 · 2012: 8
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- apolipoprotein C-III, LDL cholesterol, triglyceride-rich lipoproteins, diabetic dyslipidemia, coronary events, myocardial infarction, VLDL, atherogenic lipoproteins, apolipoprotein E, coronary risk prediction, remnant lipoproteins
- MeSH terms
- Apolipoproteins C, Cholesterol, Coronary Disease, Diabetes Mellitus, Female, Follow-Up Studies, Humans, Lipoproteins, LDL, Lipoproteins, VLDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Recurrence, Risk, Risk Factors, Triglycerides, Comorbidity, Case-Control Studies, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
